Tetraphase pharmaceuticals inc (TTPH)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12
Assets
Current assets:
Cash and cash equivalents

26,146

21,239

24,508

70,954

87,559

107,776

96,959

111,202

117,665

136,411

161,365

118,214

128,159

142,086

162,076

178,311

189,863

205,912

222,459

242,079

260,320

121,042

55,997

75,371

89,011

102,712

67,832

77,216

78,163

9,079

Accounts receivable, net

1,706

1,503

1,710

1,728

1,818

2,274

2,597

3,112

3,213

4,653

3,565

2,682

1,703

1,789

745

2,981

3,844

4,151

3,066

3,423

5,479

3,458

1,953

1,343

2,017

1,706

2,134

2,912

1,912

2,452

Contract asset

-

-

-

-

3,000

3,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Assets held for sale

-

53

544

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

788

1,595

2,434

2,964

2,348

748

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

159

121

-

-

Prepaid expenses and other current assets

1,178

2,103

2,718

3,047

2,411

2,674

5,302

6,031

6,931

6,382

5,493

5,117

3,829

6,582

6,692

5,257

7,042

3,705

2,564

2,911

3,144

2,097

2,515

1,774

1,547

1,002

2,023

674

437

850

Total current assets

29,818

26,493

31,914

78,693

97,136

116,472

104,858

120,345

127,809

147,446

170,423

126,013

133,691

150,457

169,513

186,549

200,749

213,768

228,089

248,413

268,943

126,597

60,465

78,488

92,575

105,420

72,148

80,923

80,512

12,381

Property and equipment, net

78

98

113

683

1,116

1,121

1,142

1,246

1,362

1,395

1,424

1,529

1,467

1,054

932

982

948

943

869

946

317

300

314

237

238

235

174

185

209

235

Intangible assets, net

4,160

4,259

4,357

4,455

4,553

4,652

4,750

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease right-of-use assets

2,598

4,836

5,197

5,549

5,896

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

699

699

699

699

699

699

699

199

199

199

199

199

199

199

199

199

199

199

199

199

199

199

199

199

199

199

40

40

161

161

Other assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7

38

52

106

108

109

29

31

32

451

20

28

1,295

Total assets

37,353

36,385

42,280

90,079

109,400

122,944

111,449

121,790

129,370

149,040

172,046

127,741

135,357

151,710

170,644

187,730

201,896

214,917

229,195

249,610

269,565

127,204

61,087

78,953

93,043

105,886

72,813

81,168

80,910

14,072

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable

1,977

2,429

1,752

2,079

2,692

3,210

5,203

2,119

3,599

5,306

8,893

6,918

3,595

2,555

3,621

2,542

1,490

2,857

1,735

5,786

5,595

4,105

3,737

6,724

3,925

1,881

2,916

1,963

2,033

2,018

Accrued expenses and other

-

-

-

-

-

11,761

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses

5,235

5,794

8,568

11,821

9,257

-

9,188

8,735

6,124

12,559

12,888

12,124

11,771

7,685

6,214

6,609

7,372

6,931

8,520

9,372

9,062

9,477

5,524

5,959

4,083

5,290

4,477

3,235

1,972

2,303

Deferred revenue

-

-

-

-

-

-

9

-

-

660

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

109

7,479

-

782

1,548

851

1,255

1,077

1,195

1,378

909

385

524

1,018

258

24

-

-

92

242

-

333

699

Loan payable, current portion

-

-

-

3,846

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,436

3,885

4,588

5,269

5,928

6,021

5,682

4,782

3,641

Operating lease liabilities

932

1,547

1,497

1,447

1,398

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total current liabilities

8,144

9,770

11,817

19,193

13,347

14,971

14,400

10,963

17,202

18,525

22,563

20,590

16,217

11,495

10,912

10,346

10,240

10,697

10,640

15,682

15,675

17,276

13,170

17,271

13,277

13,191

13,656

10,880

9,120

8,661

Long-term operating lease liabilities

1,754

3,448

3,850

4,239

4,621

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accrued final interest payment on term loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

222

423

-

-

327

-

-

-

-

Deferred rent, net of current portion

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

137

151

-

180

-

15

16

-

-

-

-

-

-

-

-

Loan payable

-

-

-

24,902

28,514

28,291

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,124

2,020

2,890

3,737

4,560

5,904

7,478

9,006

7,881

Total liabilities

-

-

15,667

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

610

Other long term liabilities

-

-

-

-

-

-

79

96

131

105

119

134

148

162

176

-

-

165

-

-

-

-

-

397

366

-

283

233

178

128

Commitments and contingencies (Note 11)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Convertible preferred stock, par value $0.001 per share: no shares and 259,044,157 shares authorized at December 31, 2013 and 2012, respectively; no shares and 256,024,993 shares issued and outstanding at December 31, 2013 and 2012, respectively

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

79,841

Stockholders’ equity:
Preferred stock, par value $0.001 per share; 5,000 shares authorized; no shares issued and outstanding

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Common stock, par value $0.001 per share; 125,000 shares authorized; 7,259 and 3,466 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

7

3

3

54

54

3

54

53

52

51

51

40

38

37

37

37

37

37

37

36

36

31

26

26

26

26

21

21

20

0

Additional paid-in capital

643,699

627,291

619,364

618,142

616,394

613,721

609,477

603,680

595,445

592,243

587,721

515,378

495,544

487,148

484,190

480,771

477,861

473,670

469,874

467,385

461,288

294,998

-

-

-

207,503

-

-

-

-

Additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

211,360

210,076

208,881

-

161,367

160,858

155,462

7,036

Accumulated deficit

-616,251

-604,127

-592,754

-576,451

-553,530

-534,042

-512,561

-493,002

-483,460

-461,884

-438,408

-408,401

-376,590

-347,132

-324,671

-303,561

-286,393

-269,652

-251,536

-233,493

-207,449

-186,463

-165,912

-151,707

-

-119,721

-

-

-

-

Deficit accumulated during the development stage

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

133,244

-

108,418

98,302

92,876

90,085

Total stockholders’ equity

27,455

23,167

26,613

41,745

62,918

79,682

96,970

110,731

112,037

130,410

149,364

107,017

118,992

140,053

159,556

177,247

191,505

204,055

218,375

233,928

253,875

108,566

45,474

58,395

75,663

87,808

52,970

62,577

62,606

-83,049

Total liabilities and stockholders’ equity

37,353

36,385

42,280

90,079

109,400

122,944

111,449

121,790

129,370

149,040

172,046

127,741

135,357

151,710

170,644

187,730

201,896

214,917

229,195

249,610

269,565

127,204

61,087

78,953

93,043

105,886

72,813

81,168

80,910

14,072